Table 5.

Sensitivity and specificity of InBios and NovaTec kits using samples from probable primary and secondary infections.

A. Sensitivity using confirmed ZIKV positive samples		InBios				NovaTec
Probable status	Tests used	Na	POSb	NEG	% Sensitivity (95% CI)	Nc	POS	EQ	NEG	% Sensitivity (95% CI)
Primary	RT-PCR, PRNT90	7	7	0	100.0 (64.6, 100)	7	7	0	0	100.0 (64.6, 100.0)
Primary	PRNT 90	64	54	10	84.4 (73.6, 91.3)	94	64	4	26	72.3 (62.6, 80.4)
Overalld 1° sensitivity		71	61	10	85.9 (76.0, 92.2)	101	71	4	26	74.3 (65.0, 81.8)
Secondary	RT-PCR, PRNT90	43	43	0	100.0 (91.8, 100.0)	43	34	1	8	81.4 (67.4, 90.3)
Secondary	PRNT90	0	0	0	No data	0	0	0	0	No data
Overalld 2° sensitivity		43	43	0	100.0 (91.8, 100.0)	43	34	1	8	81.4 (67.4, 90.3)
Overall sensitivity		114	104	10	91.2 (84.6, 95.2)	144	105	5	34	76.4 (68.8, 82.6)
B. Specificity using confirmed DENV positive samples		InBios				NovaTec
DEN	Tests used	Na	POSb	NEG	% Specificity (95% CI)	Nc	POS	EQ	NEG	% Specificity (95% CI)
Primary	RT-PCR, PRNT90	13	10	3	23.1 (8.2, 50.3)	13	0	0	13	100.0 (77.2, 100.0)
Primary	PRNT90	18	9	9	50.0 (29.0, 71.0)	18	0	0	18	100.0 (82.4, 100.0)
Overalld 1° specificity		31	19	12	38.7 (23.7, 56.2)	31	0	0	31	100.0 (89.0, 100.0)
Secondary	RT-PCR, PRNT90	37	35	2	5.4 (1.5, 17.7)	37	2	1	34	91.9 (78.7, 97.2)
Secondary	PRNT90	6	4	2	33.3 (9.7, 70.0)	6	0	0	6	100.0 (61.0, 100.0)
Overalld 2° specificity		43	39	4	9.3 (3.7, 21.6)	43	2	1	40	93.0 (81.4, 97.6)
Overall specificity		74	58	16	21.6 (13.8, 32.3)	74	2	1	71	95.9 (88.7, 98.6)

^aUsing results from Panels 1 and 2.

^bPresumptive and possible Zika positives classified as POS.

^cUsing results from Panels 1, 2 and 3.

^dRefers to probable infection status.